Numal (phenobarbital) is a medicine that is commonly used across conditions presenting with acute episodes to assist with certain symptoms related to systemic imbalance. Its main therapeutic use is applied in addressing symptoms related to heightened physiological activity, such as seizure disorders.

The medication is considered relevant for easing symptoms that create noticeable physiological strain. Phenobarbital is generally applied in addressing symptoms that become more disruptive during flare-ups of seizure disorders. The primary uses are applied in addressing symptoms related to heightened physiological activity (epilepsy and seizure-related symptoms), and is relevant for easing symptoms related to increased discomfort or tension, especially in settings marked by temporary physiological imbalance.

“Numal may assist with symptomatic management in conditions where functional stability becomes affected, helping patients cope more steadily with symptom fluctuations.”

The medicine may be applied across domains where additional symptomatic support is needed. It contributes to easing the overall symptom load.

Quick Fact: May Assist with Symptoms of Heightened Physiological Activity

Regulatory References

1. NIH MedlinePlus information on Phenobarbital

The eligibility for Numal (Atovaquone and Proguanil Hydrochloride) is strictly defined by government regulatory documents, focusing on absolute contraindications and population limitations.

Eligibility Scope

Connection to the Overall Eligibility Profile

The official documents define Numal's eligibility profile by establishing absolute prohibitions based on component intolerance and a threshold of severe renal impairment for prophylaxis. Eligibility is further structured by minimum body weight requirements for pediatric use and by specific cautionary restrictions for patients with severe gastrointestinal symptoms or underlying organ impairment.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Numal (Atovaquone and Proguanil Hydrochloride), based strictly on regulatory prescribing information.

Official Regulatory Restrictions

The co-administration of Numal with certain medicinal products is not recommended due to the significant risk of decreased drug exposure, which may impact effectiveness. Regulatory documents explicitly advise against the use of Rifampicin and Rifabutin with Numal as they substantially reduce the plasma concentrations of Atovaquone.

Documented Exposure-Altering Interactions

Several agents are noted in official labeling for their ability to modify the plasma levels of Numal or vice versa:

• Antiretroviral Agents: Co-administration with agents such as Efavirenz or Lopinavir/Ritonavir has been shown to cause substantial decreases in Atovaquone concentrations.
• Anticoagulants: Proguanil may potentiate the anticoagulant effect of Warfarin and other coumarin-based drugs, requiring close monitoring of coagulation tests.
• Other Agents: Tetracycline and Metoclopramide have been associated with reduced Atovaquone exposure.

Administration and Population Notes

The absorption of Atovaquone is significantly enhanced when Numal is administered with food or a milky drink. Additionally, official prescribing information restricts the use of Numal for malaria prophylaxis in specific populations. The combination is contraindicated for prophylaxis in patients with severe renal impairment (creatinine clearance <30 mL/min).

How Numal Works: Dual-Action Parasite Elimination

Numal, a combination of Atovaquone and Proguanil Hydrochloride, acts by targeting two distinct and essential metabolic systems within the Plasmodium parasite. This dual-action mechanism requires the parasite to develop resistance mutations in two separate pathways simultaneously.

Blocking Mitochondrial Energy and Replication

The compound Atovaquone acts as a competitive inhibitor of the Cytochrome bc1 complex within the parasite's mitochondrion. This molecular action immediately disrupts the electron transport chain, causing the parasite's membrane potential (DeltaPsim) to collapse, which dissipates the proton gradient essential for ATP synthesis. This collapse also indirectly prevents the synthesis of pyrimidines, the fundamental building blocks for parasitic DNA and RNA. This combined molecular failure results in the cessation of replication.

Interfering with Folate-Dependent DNA Synthesis

The mechanism is complemented by the action of Cycloguanil, the active metabolite of Proguanil. Cycloguanil inhibits the enzyme Dihydrofolate Reductase (DHFR), which is crucial for the production of tetrahydrofolate (THF). By blocking THF synthesis, the pathway fails to generate sufficient precursors for deoxythymidylate—a final component required for DNA production. This dual-pathway interference prevents the parasite from producing energy and halts the synthesis of its genetic material, thereby impeding the proliferation of the schizonts.

The administration of Numal (Atovaquone and Proguanil Hydrochloride) follows specific, structured instructions defining the schedule, dosing, and conditions of intake.

Administration Scope

The required once-daily oral intake ensures consistent systemic drug levels, while the mandatory intake with food is necessary to maximize absorption. The prophylaxis regimen involves starting the daily dose 1 to 2 days before entering the endemic area and continuing it for 7 consecutive days after departure. If vomiting occurs within 1 hour of dosing, a repeat, full dose should be taken. These instructions define a time-bound, daily, and food-dependent course of use.

Research Evidence / Overview of Studies for Numal

This section summarizes the structure of the clinical evidence for the two distinct medications marketed as Numal: the anti-malarial combination of Atovaquone and Proguanil Hydrochloride and the anti-seizure medication Phenobarbital. The purpose of this summary is to describe what has been observed in group research settings, not to provide clinical advice or guarantee individual outcomes.

I. Research Evidence for Numal (Atovaquone and Proguanil Hydrochloride)

Studies for malaria prevention have been evaluated using short-term Randomized Controlled Trials (RCTs) and systematic reviews, monitoring the incidence of malaria (protective efficacy) in non-immune travelers and semi-immune residents. Research measured the proportion of subjects who remained parasite-free during the observed period compared to control groups examined in trials.

For acute malaria treatment, clinical trials monitored parasite clearance rates and the incidence of treatment failure at set follow-up points (e.g., Day 28 and Day 42). Studies explored how the drug was observed in areas where parasite resistance was a factor in the study design.

II. Research Evidence for Numal (Phenobarbital)

Research for seizure management was studied using comparative controlled trials and long-running observational cohort studies. Studies monitored seizure frequency reduction and the rate of achieving a seizure-free status, with some long-term studies tracking patients over many years. For acute withdrawal symptom management, research was explored using prospective observational cohorts focusing on episodes where symptoms become more noticeable in hospitalized settings. Findings describe patterns observed in the studies regarding symptom severity and stabilization during acute treatment.

What Is Still Uncertain about Numal

Data for certain groups remain insufficient. For the anti-malarial combination, this includes very low-weight pediatric subjects. For Phenobarbital, the extent of research is limited for older adults. Additionally, long-term effects are not fully established regarding measures of cognition and development, especially when Phenobarbital is compared with newer anti-seizure agents. Evidence highlights what is known—and what is still uncertain.

Common questions about Numal (FAQ)

Q: Can I stop taking Numal when I feel better?

The official prescribing information generally advises against suddenly stopping treatment, even if symptoms appear to improve. Stopping Numal abruptly may be associated with withdrawal symptoms or a return of the original condition.

Any changes to the medication schedule, including discontinuation, should only be made under the guidance of a healthcare professional. A healthcare provider can determine the appropriate method for stopping treatment, which may involve a gradual dosage reduction over a period of time. Following the healthcare provider's instructions for discontinuation is important for managing potential effects.

Q: What happens if I miss a dose of Numal?

Instructions for a missed dose can vary, so it is important to refer to the specific guidance provided by your prescriber or the patient information leaflet.

Generally, the recommendation for a missed dose is often to take it as soon as it is remembered, unless it is close to the time of the next scheduled dose. If it is close to the time of the next dose, the official instructions typically advise patients to skip the missed dose and resume the normal schedule.

It is generally advised not to take two doses at once to compensate for a forgotten one. Individuals who frequently miss doses should consult their healthcare provider or pharmacist for personalized management strategies.

Q: Does Numal cause weight gain?

Weight gain has been identified as a commonly reported side effect in clinical trials of Numal. The degree of weight change can vary significantly between individuals. Some clinical data indicates patients may experience weight changes during treatment.

Monitoring body weight and reporting any significant, unexpected changes to a healthcare professional is recommended. General measures like maintaining a balanced diet and regular physical activity may be beneficial, but specific weight management plans should be discussed with a healthcare provider for personalized advice.

How to Store and Dispose of Numal (Phenobarbital)

Numal must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), while protecting it from both light and excess moisture. The container must be kept tightly closed and away from excess heat. For liquid forms, do not freeze.

As a Schedule IV controlled substance, the medication must be stored locked up and maintained out of the sight and reach of children.

Disposal of unused or expired Numal should follow an authorized drug take-back program. If a program is unavailable, mix the medication with an undesirable substance, seal it in a container, and discard it in the trash. Do not flush Numal down the toilet or allow it to enter drains.